[{"data":1,"prerenderedAt":153},["ShallowReactive",2],{"drug-cytarabine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":16,"formulations":20,"regimens":34,"contraindications":52,"warnings":62,"renal":71,"monitoring":72,"interactions":73,"review":74,"examples":77,"atc":78,"iran":80,"usApproval":120,"links":126,"populations":143},"cytarabine",1,{"fa":7,"en":8},"سیتارابین","Cytarabine","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتی‌متابولیت پیریمیدین","Pyrimidine antimetabolite",[14],{"name":8,"market":15},"US",[17,18,19,7],"ara-c","cytosar","سیتوزار",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"vial-20","injection","iv","20 mg\u002FmL (500 mg\u002F25 mL)",{"amount":27,"unit":28,"perVolumeMl":5},20,"mg",[15],[31],{"source":32,"section":33},"fda-cytarabine","How Supplied",[35],{"id":36,"disease":37,"label":38,"population":41,"type":42,"unit":28,"dose":43,"refs":47},"aml","acute-myeloid-leukemia",{"fa":39,"en":40},"القای بهبودی لوسمی حاد غیرلنفوسیتی (AML)، ALL و فاز بلاستی CML — طبق پروتکل","Remission induction in acute non-lymphocytic leukaemia (AML), ALL and CML blast phase — per protocol",{},"notCalculated",{"reason":44},{"fa":45,"en":46},"برنامه و روش تجویز (انفوزیون مداوم، بولوس یا زیرجلدی) به پروتکل بستگی دارد؛ دوز قطعی از پروتکل درمانی انکولوژی گرفته شود. شمارش روزانه لکوسیت و پلاکت حین القا. فرم بدون نگهدارنده برای تزریق داخل نخاعی.","Schedule and route (continuous infusion, bolus or SC) depend on the protocol; take the exact dose from the oncology protocol. Daily leukocyte and platelet counts during induction. Only preservative-free product intrathecally.",[48,50],{"source":32,"section":49},"Dosage and Administration",{"source":32,"section":51},"Warnings",[53],{"id":54,"severity":55,"text":56,"refs":59},"hyper","block",{"fa":57,"en":58},"حساسیت به سیتارابین.","Hypersensitivity to cytarabine.",[60],{"source":32,"section":61},"Contraindications",[63],{"text":64,"refs":67},{"fa":65,"en":66},"هشدار جعبه‌ای: فقط زیر نظر پزشک مجرب؛ سرکوب قوی مغز استخوان — شمارش روزانه در القا.","Boxed warning: only by experienced physicians; potent bone-marrow suppression — daily counts during induction.",[68,70],{"source":32,"section":69},"Boxed Warning",{"source":32,"section":51},[],[],[],{"status":75,"reviewer":76,"date":76},"unverified",null,[],[79],"L01BC01",{"status":81,"forms":82,"refs":115},"registered",[83,87,91,95,99,103,107,111],{"code":84,"en":85,"fa":86},"00375","CYTARABINE 100MG\u002F5ML VIAL","ویال سیتارابین ۱۰۰ میلی‌گرم \u002F ۵ میلی‌لیتر",{"code":88,"en":89,"fa":90},"01454","CYTARABINE 1G VIAL","ویال سیتارابین ۱ گرم",{"code":92,"en":93,"fa":94},"18976","CYTARABINE 40MG\u002F2MLVIAL","سیتارابین ۴۰ میلی‌گرم \u002F ۲ ملویال",{"code":96,"en":97,"fa":98},"50464","CYTARABINE INJECTION, SOLUTION, CONCENTRATE PARENTERAL 50 mg\u002F1mL 20 mL","کنسانتره محلول تزریقی سیتارابین ۵۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۲۰ میلی‌لیتر",{"code":100,"en":101,"fa":102},"52394","CYTARABINE INJECTION, SOLUTION PARENTERAL 100 mg\u002F1mL 10 mL","محلول تزریقی سیتارابین ۱۰۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰ میلی‌لیتر",{"code":104,"en":105,"fa":106},"52393","CYTARABINE INJECTION, POWDER, FOR SOLUTION PARENTERAL 100 mg","پودر برای تهیه محلول تزریقی سیتارابین ۱۰۰ میلی‌گرم",{"code":108,"en":109,"fa":110},"52404","CYTARABINE INJECTION, SOLUTION, CONCENTRATE PARENTERAL 20 mg\u002F1mL 50 mL","کنسانتره محلول تزریقی سیتارابین ۲۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۵۰ میلی‌لیتر",{"code":112,"en":113,"fa":114},"52791","CYTARABINE INJECTION, SOLUTION PARENTERAL 100 mg\u002F1mL 1 mL","محلول تزریقی سیتارابین ۱۰۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۱ میلی‌لیتر",[116],{"source":117,"section":118,"url":119},"darooyab-generic","G-976\u002FCytarabine","https:\u002F\u002Fwww.darooyab.ir\u002FG-976\u002FCytarabine",{"kind":121,"refs":122,"id":125},"ANDA",[123],{"source":32,"section":124},"SPL approval \u002F marketing category","ANDA072945",[127,130,134,138,141],{"kind":128,"url":129,"label":125},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=072945",{"kind":131,"url":132,"label":133},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=21e8e8e6-3f85-4fdd-8452-c9d14d2ef69a","FDA Cytarabine",{"kind":135,"url":136,"label":137},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682222.html","Cytarabine Injection",{"kind":139,"url":140,"label":79},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01BC01",{"kind":142,"url":119,"label":8},"darooyab",{"pregnancy":144},{"level":145,"text":146,"quote":149,"refs":150},"caution",{"fa":147,"en":148},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","A review of the literature has shown 32 reported cases where cytarabine was given during pregnancy, either alone or in combination with other cytotoxic agents.",[151],{"source":32,"section":152},"Precautions\u002FWarnings – Pregnancy",1792444709736]